Have a feature idea you'd love to see implemented?
Let us know!
SPRO Spero Therapeutics Inc
Price (delayed)
$1.24
Market cap
$67.02M
P/E Ratio
3.65
Dividend/share
N/A
EPS
$0.34
Enterprise value
$8.43M
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Highlights
SPRO's revenue has soared by 118% YoY and by 7% from the previous quarter
The gross profit has soared by 118% YoY and by 7% from the previous quarter
The EPS has surged by 183% year-on-year but it has declined by 23% since the previous quarter
The equity has increased by 47% year-on-year but it has declined by 16% since the previous quarter
SPRO's quick ratio is down by 32% year-on-year and by 18% since the previous quarter
The net income has contracted by 25% from the previous quarter
Key stats
What are the main financial stats of SPRO
Market
Valuations
Earnings
Shares outstanding
54.05M
Market cap
$67.02M
Enterprise value
$8.43M
Price to earnings (P/E)
3.65
Price to book (P/B)
0.83
Price to sales (P/S)
0.56
EV/EBIT
0.42
EV/EBITDA
0.42
EV/Sales
0.07
Revenue
$118.46M
EBIT
$20.05M
EBITDA
$20.2M
Free cash flow
-$14.38M
Per share
Balance sheet
Liquidity
EPS
$0.34
Free cash flow per share
-$0.27
Book value per share
$1.49
Revenue per share
$2.2
TBVPS
$2.78
Total assets
$149.88M
Total liabilities
$69.38M
Debt
$4.94M
Equity
$80.5M
Working capital
$76.59M
Debt to equity
0.06
Current ratio
2.68
Quick ratio
3.13
Net debt/EBITDA
-2.9
Margins
Efficiency
Dividend
EBITDA margin
17.1%
Gross margin
100%
Net margin
14.7%
Operating margin
13.1%
Return on assets
11.5%
Return on equity
20.7%
Return on invested capital
49.3%
Return on capital employed
19.2%
Return on sales
16.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRO stock price
How has the Spero Therapeutics stock price performed over time
Intraday
0%
1 week
-5.34%
1 month
-9.49%
1 year
7.83%
YTD
-15.65%
QTD
-7.46%
Financial performance
How have Spero Therapeutics's revenue and profit performed over time
Revenue
$118.46M
Gross profit
$118.46M
Operating income
$15.56M
Net income
$17.46M
Gross margin
100%
Net margin
14.7%
The net margin has surged by 179% year-on-year but it has declined by 30% since the previous quarter
SPRO's operating margin has surged by 155% year-on-year but it is down by 33% since the previous quarter
SPRO's revenue has soared by 118% YoY and by 7% from the previous quarter
The gross profit has soared by 118% YoY and by 7% from the previous quarter
Growth
What is Spero Therapeutics's growth rate over time
Valuation
What is Spero Therapeutics stock price valuation
P/E
3.65
P/B
0.83
P/S
0.56
EV/EBIT
0.42
EV/EBITDA
0.42
EV/Sales
0.07
The EPS has surged by 183% year-on-year but it has declined by 23% since the previous quarter
The price to book (P/B) is 67% less than the 5-year quarterly average of 2.5 and 8% less than the last 4 quarters average of 0.9
The equity has increased by 47% year-on-year but it has declined by 16% since the previous quarter
SPRO's revenue has soared by 118% YoY and by 7% from the previous quarter
SPRO's P/S is 96% below its 5-year quarterly average of 14.1 and 20% below its last 4 quarters average of 0.7
Efficiency
How efficient is Spero Therapeutics business performance
The return on sales has surged by 191% year-on-year but it has declined by 28% since the previous quarter
SPRO's ROIC has soared by 118% YoY but it is down by 40% QoQ
The return on assets has declined by 32% since the previous quarter
Spero Therapeutics's ROE has decreased by 31% from the previous quarter
Dividends
What is SPRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRO.
Financial health
How did Spero Therapeutics financials performed over time
SPRO's total assets is 116% higher than its total liabilities
SPRO's total liabilities has surged by 57% year-on-year but it is down by 2.9% since the previous quarter
SPRO's total assets has soared by 52% YoY but it is down by 11% QoQ
The debt is 94% smaller than the equity
The equity has increased by 47% year-on-year but it has declined by 16% since the previous quarter
The debt to equity has contracted by 45% YoY but it has grown by 20% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.